Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With PLATO Major Bleeding Event
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.00473 | 0.00334 | 0.00671 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.00577 | 0.00421 | 0.00792 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00104 | -0.0036 | 0.00148 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.82 | 0.511 | 1.32 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.819 | 0.509 | 1.32 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Ticagrelor 90 mg than on ASA 100 mg | 961 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Ticagrelor 90 mg | Ticagrelor 90 mg twice daily (BD) | 31 | 6,549 | OG000 | ClinicalTrials.gov |
| Group 2 | ASA 100 mg | ASA 100 mg once daily (OD) | 38 | 6,581 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants With PLATO Major Bleeding Event | ClinicalTrials.gov |
| Description | Participants with PLATO Major bleeding. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).~PLATO Major bleeding is defined as a bleed that is any one of:~* Fatal~* Intracranial (excluding asymptomatic haemorrhagic transformations of ischemic brain infarctions and excluding micro-hemorrhages \<10 mm evident only on gradient-echo MRI)~* Intrapericardial bleed with cardiac tamponade~* Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery~* Significantly disabling (eg. intraocular with permanent vision loss)~* Clinically overt or apparent bleeding associated with a decrease in Hb of more than 30 g/L (1.9 mmol/L; 0.465 mmol/L)~* Transfusion of 2 or more units (whole blood or packed red blood cells \[PRBCs\]) for bleeding. | ClinicalTrials.gov |
| Time frame | From randomization up to 97 days | ClinicalTrials.gov |
| Population | The population was the safety analysis set, which included all patients who received at least 1 dose of randomized ticagrelor or ASA and for whom post-dose data are available. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] | ClinicalTrials.gov |
| NCT number | NCT01994720 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Acute Ischaemic Stroke, Transient Ischaemic Attack | ClinicalTrials.gov |
| Interventions | ticagrelor, Acetylsalicylic acid (ASA) | ClinicalTrials.gov |
| Lead sponsor | AstraZeneca | ClinicalTrials.gov |
| Results first posted | 2017-06-12 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01994720?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.